Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Laryngoscope. 2014 Jun;124(6):1452-8. doi: 10.1002/lary.24537. Epub 2014 Jan 15.
OBJECTIVES/HYPOTHESIS: To determine the cost-effectiveness of bilateral cochlear implantation (CI) in deaf adults.
Cost-utility analysis.
Ninety patients and 52 health professionals served as proxies to estimate the benefit of bilateral cochlear implantation, utilizing the Health Utility Index. Three scenarios were created to reflect 1) deafness without intervention, 2) unilateral CI, and 3) bilateral CI. Cost evaluation reflected the burden on a publicly funded healthcare system. The base case included 25 years of service provision, processor upgrades every 5 years, 50% price reduction for second side, and 15% failure rate. Discounting and sensitivity analyses were applied.
Costs were $63,632 (unilateral CI), $111,764 (bilateral CI), and $48,132 (incremental cost of second CI). The health preference gained from no intervention to unilateral CI, and to bilateral CI were 0.270 and 0.305. Incremental utility gained by the second implant was 11.5% of total. The incremental cost-utility ratio (ICUR) was $14,658/quality-adjusted life year (QALY) for bilateral CI compared to no intervention. It was stable regardless of discounting or sensitivity analyses. ICUR was $55,020/QALY from unilateral to bilateral CI with higher uncertainties. It improved with differential discounting, further second-side price reduction, and reduced frequency of processor upgrades. ICUR worsened with reduced length of use and higher failure rates.
Sequential bilateral CI was cost-effective when compared to no intervention, although gains were made mostly by the first implant. Cost-effectiveness compared to unilateral implantation was borderline but improved through base case variations to reflect long-term gains or cost-saving measures.
2C.
目的/假设:确定双侧人工耳蜗植入(CI)在聋人成人中的成本效益。
成本效益分析。
90 名患者和 52 名健康专业人员作为代理人,使用健康效用指数估计双侧人工耳蜗植入的获益。创建了三个场景来反映 1)不干预的耳聋,2)单侧 CI,和 3)双侧 CI。成本评估反映了对公共资助医疗保健系统的负担。基础案例包括 25 年的服务提供,每 5 年升级处理器,第二侧价格降低 50%,以及 15%的失败率。应用了折扣和敏感性分析。
单侧 CI 的成本为 63632 美元,双侧 CI 的成本为 111764 美元,第二侧 CI 的增量成本为 48132 美元。从不干预到单侧 CI,再到双侧 CI 的健康偏好分别为 0.270 和 0.305。第二植入物获得的增量效用占总效用的 11.5%。与不干预相比,双侧 CI 的增量成本效益比(ICUR)为每质量调整生命年(QALY)14658 美元。无论是否贴现或进行敏感性分析,结果均稳定。从单侧 CI 到双侧 CI 的 ICUR 为 55020 美元/QALY,但存在更高的不确定性。通过差异贴现、进一步降低第二侧价格和减少处理器升级频率,可以改善这一结果。随着使用时间缩短和失败率增加,ICUR 恶化。
与不干预相比,序贯双侧 CI 具有成本效益,尽管收益主要来自第一侧植入物。与单侧植入相比,成本效益具有边缘性,但通过基础案例的变化可以改善,以反映长期获益或成本节约措施。
2C。